Physician profile
Lyle E Cartwright
NPI 1750380762
$639.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $72.11 · 2021: $75.27 · 2022: $29.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $182.39 | 2019-2021 | |
| Pfizer INC. | $85.36 | 2019-2021 | |
| Genzyme Corporation | $77.09 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $71.68 | 2019 | |
| Amgen INC. | $48.26 | 2019 | |
| Janssen Biotech, INC. | $44.36 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.50 | 2019 | |
| Celgene Corporation | $20.06 | 2019 | |
| Ucb, INC. | $19.25 | 2019 | |
| Mayne Pharma Commercial LLC | $14.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.02 | 2019 | |
| Allergan, INC. | $13.45 | 2022 | |
| Prugen, INC. Pharmaceuticals | $10.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyle Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.